PPAR-γ, as a master regulator of hepatic lipid homeostasis, demonstrates therapeutic potential for NAFLD treatment through its anti-inflammatory, insulin-sensitizing, oxidative stress-alleviating, and fibrotic regression properties [66]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.